Stay updated with breaking news from Intima Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The roles of Chairman and Chief Executive Officer will be separated. Dr. Riva proposed as new independent Director and non-executive Chairman of the Board. With more than 30 years of experience
GAITHERSBURG, Md., March 22, 2022 /PRNewswire/ -- MaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
MaxCyte inks platform pact with Intima Bioscience
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.